WolverHeme Happy Hour

By: Bernard Marini Anthony Perissinotti et al.
  • Summary

  • Welcome to WolverHeme Happy Hour! This is a podcast dedicated to all things hematology! We discuss new data, debate controversial therapies, and talk about new and exciting research. While we nerd out about data, we'll have a few drinks! Disclaimer: The views and opinions expressed on this podcast are solely those of the podcasters and guests and do not reflect the views or opinions of our employers or other affiliations.
    Bernard Marini, Anthony Perissinotti, et al.
    Show More Show Less
activate_Holiday_promo_in_buybox_DT_T2
Episodes
  • Pour Decisions, or ASH-olutely Fabulous? Reviewing 2024 ASH Lymphoma Updates
    Dec 24 2024

    In this episode released just in time for the holidays, Anthony and Bernie are joined by Tycel Phillips, MD to discuss the most exciting updates from ASH 2024 in lymphoma! Pour yourself a drink and have a listen!

    Some selected abstracts:

    • EA4151: https://ash.confex.com/ash/2024/webprogram/Paper212973.html
    • Triangle Updates: https://ash.confex.com/ash/2024/webprogram/Paper200735.html , https://ash.confex.com/ash/2024/webprogram/Paper201441.html
    • EA4181: https://ash.confex.com/ash/2024/webprogram/Paper194641.html
    • ENRICH: https://ash.confex.com/ash/2024/webprogram/Paper199710.html
    • inMIND: https://ash.confex.com/ash/2024/webprogram/Paper212970.html
    • POLARIX Long-Term F/U: https://ash.confex.com/ash/2024/webprogram/Paper197938.html
    Show More Show Less
    1 hr and 4 mins
  • A Bunch of ASHholes Discuss Myeloma Abstracts
    Nov 16 2024

    In this episode, Anthony and Bernie are joined by Dr. Aaron "Papa Heme" Goodman and Dr. Manni "Myeloma Man" Mohyuddin to discuss the most intriguing ASH 2024 abstracts! Should any of the research from ASH 2024 change your practice? Find out!

    Show More Show Less
    56 mins
  • Cast your vote! Nivolumab vs. Brentuximab for Classical Hodgkin Lymphoma
    Nov 8 2024

    In this episode, Bernie and Anthony are joined by two special guest expert hematologists:

    Dr. David Russler-Germain

    Dr. Tycel Phillips

    We discuss recent updates in the treatment of upfront Classical Hodgkin Lymphoma, including whether the SWOG S1826 and HD21 trials change practice! Will it be a landslide victory for nivolumab? Is brentuximab fired?

    Stay tuned to find out!

    Show More Show Less
    48 mins

What listeners say about WolverHeme Happy Hour

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.